CoChat
Sign Up
Cited by 192

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

High-throughput Phenotyping of Lung Cancer Somatic Mutations

Berger, Alice H., Brooks, Angela N., Wu, Xiaoyun, Shrestha, Yashaswi, Chouinard, Candace, Piccioni, Federica, Bagul, Mukta, Kamburov, Atanas, Imielinski, Marcin, Hogstrom, Larson, Zhu, Cong, Yang, Xiaoping, Pantel, Sasha, Sakai, Ryo, Watson, Jacqueline, Kaplan, Nathan, Campbell, Joshua D., Singh, Shantanu, Root, David E., Narayan, Rajiv, Natoli, Ted, Lahr, David L., Tirosh, Itay, Tamayo, Pablo, Getz, Gad, Wong, Bang, Doench, John, Subramanian, Aravind, Golub, Todd R., Meyerson, Matthew, Boehm, Jesse S.·2016·Cancer Cell
DOI 10.1016/j.ccell.2016.06.022PMC PMC5003022
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2016.06.022

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 33

  1. Berger, 2014, Oncogenic RIT1 mutations in lung adenocarcinoma, Oncogene, 33, 4418, 10.1038/onc.2013.581 · DOI
  2. Berns, 2004, A large-scale RNAi screen in human cells identifies new components of the p53 pathway, Nature, 428, 431, 10.1038/nature02371 · DOI
  3. Boehm, 2007, Integrative genomic approaches identify IKBKE as a breast cancer oncogene, Cell, 129, 1065, 10.1016/j.cell.2007.03.052 · DOI
  4. Bric, 2009, Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model, Cancer Cell, 16, 324, 10.1016/j.ccr.2009.08.015 · DOI
  5. Davoli, 2013, Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome, Cell, 155, 948, 10.1016/j.cell.2013.10.011 · DOI · Paper page
  6. Dunn, 2014, In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene, Proc. Natl. Acad. Sci. USA, 111, 1102, 10.1073/pnas.1311909111 · DOI
  7. Ebert, 2008, Identification of RPS14 as a 5q- syndrome gene by RNA interference screen, Nature, 451, 335, 10.1038/nature06494 · DOI
  8. Emery, 2009, MEK1 mutations confer resistance to MEK and B-RAF inhibition, Proc. Natl. Acad. Sci. USA, 106, 20411, 10.1073/pnas.0905833106 · DOI
  9. Frohling, 2007, Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles, Cancer Cell, 12, 501, 10.1016/j.ccr.2007.11.005 · DOI
  10. Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI
  11. Imielinski, 2014, Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma, J. Clin. Invest., 124, 1582, 10.1172/JCI72763 · DOI
  12. Jaramillo, 2013, The emerging role of the Nrf2-Keap1 signaling pathway in cancer, Genes Dev., 27, 2179, 10.1101/gad.225680.113 · DOI
  13. Kilpivaara, 2013, Diagnostic cancer genome sequencing and the contribution of germline variants, Science, 339, 1559, 10.1126/science.1233899 · DOI
  14. Kim, 2016, Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles, Cancer Discov., 6, 714, 10.1158/2159-8290.CD-16-0160 · DOI
  15. Kitzman, 2015, Massively parallel single-amino-acid mutagenesis, Nat. Methods, 12, 203, 10.1038/nmeth.3223 · DOI
  16. Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N. Engl. J. Med., 363, 1693, 10.1056/NEJMoa1006448 · DOI
  17. Lamb, 2006, The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 · DOI · Paper page
  18. Malhotra, 2010, Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis, Nucleic Acids Res., 38, 5718, 10.1093/nar/gkq212 · DOI
  19. Melnikov, 2014, Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes, Nucleic Acids Res., 42, e112, 10.1093/nar/gku511 · DOI
  20. Ng, 2003, SIFT: predicting amino acid changes that affect protein function, Nucleic Acids Res., 31, 3812, 10.1093/nar/gkg509 · DOI
  21. Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. USA, 101, 13306, 10.1073/pnas.0405220101 · DOI · Paper page
  22. Parnas, 2015, A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks, Cell, 162, 675, 10.1016/j.cell.2015.06.059 · DOI · Paper page
  23. Peck, 2006, A method for high-throughput gene expression signature analysis, Genome Biol., 7, R61, 10.1186/gb-2006-7-7-r61 · DOI
  24. Reva, 2011, Predicting the functional impact of protein mutations: application to cancer genomics, Nucleic Acids Res., 39, e118, 10.1093/nar/gkr407 · DOI
  25. Roychowdhury, 2011, Personalized oncology through integrative high-throughput sequencing: a pilot study, Sci. Transl. Med., 3, 111ra121, 10.1126/scitranslmed.3003161 · DOI
  26. Sawey, 2011, Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening, Cancer Cell, 19, 347, 10.1016/j.ccr.2011.01.040 · DOI
  27. Sharifnia, 2014, Genetic modifiers of EGFR dependence in non-small cell lung cancer, Proc. Natl. Acad. Sci. USA, 111, 18661, 10.1073/pnas.1412228112 · DOI
  28. Stratton, 2009, The cancer genome, Nature, 458, 719, 10.1038/nature07943 · DOI
  29. Taylor, 2015, Factors influencing success of clinical genome sequencing across a broad spectrum of disorders, Nat. Genet., 47, 717, 10.1038/ng.3304 · DOI
  30. Van Allen, 2014, Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nat. Med., 20, 682, 10.1038/nm.3559 · DOI
  31. Wagle, 2012, High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing, Cancer Discov., 2, 82, 10.1158/2159-8290.CD-11-0184 · DOI
  32. Wilson, 2015, A functional landscape of resistance to ALK inhibition in lung cancer, Cancer Cell, 27, 397, 10.1016/j.ccell.2015.02.005 · DOI
  33. Zender, 2008, An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer, Cell, 135, 852, 10.1016/j.cell.2008.09.061 · DOI

Cited by

Sorted by citations

See all 192

Metadata

Authors
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., Zhu, C., Yang, X., Pantel, S., Sakai, R., Watson, J., Kaplan, N., Campbell, J. D., Singh, S., Root, D. E., Narayan, R., Natoli, T., Lahr, D. L., Tirosh, I., Tamayo, P., Getz, G., Wong, B., Doench, J., Subramanian, A., Golub, T. R., Meyerson, M., & Boehm, J. S.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2016-08
Volume
30
Issue
2
Pages
214-228
ISSN
1535-6108
DOI
10.1016/j.ccell.2016.06.022
PMC
PMC5003022
Cited by
192
References
17
Language
en
Update notices
erratum (2017-12-11)
Licence
Funders
  • American Cancer Society (122398-PF-12-080-01-TBG)
  • National Cancer Institute (1R35CA197568)
  • Damon Runyon Cancer Research Foundation (DRG-2138-12)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review